Skip to main content

Shockwave Medical Reports Third Quarter 2022 Financial Results

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022.

Recent Highlights

  • Recognized revenue of $131.3 million for the third quarter of 2022, representing an increase of 102% from the same period in 2021
  • Received FDA Clearance for the Shockwave IVL System with the Shockwave L6 Peripheral IVL Catheter
  • Received CE marking for the Shockwave C2+ coronary catheter in Europe
  • Granted reimbursement for the Shockwave C2 Coronary IVL Catheter by the Japanese Ministry of Health, Labour and Welfare (MHLW) in Japan

“Our third quarter achievements were encouraging across the entire Shockwave organization. Sales of all products, both in the U.S. and international markets, outperformed expectations, and operationally our accomplishments continue to be the backbone of our success,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “These results were particularly impressive in light of the many ongoing macro issues we have all seen across the globe. Despite these challenges, our team and our customers have been able to adapt and remain focused on using our IVL technology to treat patients suffering from calcified vascular disease.”  

Third Quarter 2022 Financial Results

Revenue for the third quarter ended September 30, 2022, was $131.3 million, a 102% increase from $65.2 million in the same period of 2021. The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February 2021, continued recovery from the pandemic impact and increased adoption of Shockwave products.

Gross profit for the third quarter of 2022 was $113.5 million compared to $54.2 million for the third quarter of 2021. Gross margin for the third quarter of 2022 was 86%, as compared to 83% in the third quarter of 2021. The increase in gross margin was primarily driven by product mix along with continued improvement in manufacturing productivity and process efficiencies.

Total operating expenses for the third quarter of 2022 were $76.7 million, a 49% increase from $51.4 million in the third quarter of 2021. The increase was primarily driven by sales force expansion in the U.S. and higher headcount to support the growth of the business.

Net income for the third quarter of 2022 was $35.0 million, compared to net income of $1.9 million in the same period of 2021. Basic and diluted net income per share for the third quarter of 2022 was $0.97 and $0.92, respectively.  

Cash, cash equivalents and short-term investments totaled $250.7 million as of September 30, 2022.

2022 Financial Guidance

Shockwave Medical projects revenue for the full year 2022 to range from $483 million to $488 million, which represents 104% to 106% growth over the Company’s prior year revenue. This compares to previous revenue guidance of $465 million to $475 million.

Conference Call

Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, November 7, 2022, to discuss its third quarter 2022 financial results. The call may be accessed by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID:13733213.   A live and archived webcast of the event will be available at

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit

Forward-Looking Statements

This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the impact of the COVID-19 pandemic on our operations, financial results, and liquidity and capital resources, including the impact on our sales, expenses, supply chain, manufacturing, research and development activities, clinical trials, and employees; our ability to develop, manufacture, obtain and maintain regulatory approvals for, market and sell, our products; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures performed using our products; our ability to scale our organizational culture; the impact of the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or management personnel; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial performance and capital requirements; and our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, and in our other periodic and other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

Media Contact:
Scott Shadiow

Investor Contact:
Debbie Kaster

Balance Sheet Data
(in thousands)
  September 30,
 December 31,
Cash and cash equivalents $127,779  $89,209 
Short-term investments  122,888   111,772 
Accounts receivable, net  64,224   37,435 
Inventory  68,974   42,978 
Prepaid expenses and other current assets  11,393   4,508 
     Total current assets  395,258   285,902 
Operating lease right-of-use assets  33,107   27,496 
Property and equipment, net  39,265   24,361 
Equity method investment  4,573   5,987 
Other assets  3,606   1,936 
TOTAL ASSETS $475,809  $345,682 
Accounts payable $3,469  $3,520 
Term notes, current portion     5,500 
Accrued liabilities  49,492   40,870 
Lease liability, current portion  1,260   1,738 
     Total current liabilities  54,221   51,628 
Lease liability, noncurrent  38,532   28,321 
Term notes, noncurrent portion  14,853   11,630 
Related party contract liability, noncurrent portion  12,273   12,273 
TOTAL LIABILITIES  119,879   103,852 
Preferred stock      
Common stock  36   35 
Additional paid-in capital  535,230   494,806 
Accumulated other comprehensive loss  (1,612)  (202)
Accumulated deficit  (177,724)  (252,809)
TOTAL STOCKHOLDERS’ EQUITY  355,930   241,830 

Statement of Operations Data
(in thousands, except share and per share data)
  Three Months Ended Nine Months Ended
  September 30, September 30,
   2022   2021   2022   2021  
Product revenue $131,330  $65,155  $345,707  $152,963  
Cost of revenue:         
Cost of product revenue  17,874   10,949   47,494   28,775  
     Gross profit  113,456   54,206   298,213   124,188  
Operating expenses:         
Research and development  20,177   13,735   57,956   35,827  
Sales and marketing  42,082   28,393   118,558   78,098  
General and administrative  14,434   9,265   39,988   25,117  
     Total operating expenses  76,693   51,393   216,502   139,042  
Income (loss) from operations  36,763   2,813   81,711   (14,854) 
Income (loss) from equity method investment  97   (342)  (1,414)  (5,865) 
Interest expense  (316)  (165)  (917)  (795) 
Other expense, net  (1,423)  (280)  (3,206)  (369) 
Net income (loss) before taxes  35,121   2,026   76,174   (21,883) 
Income tax provision  118   78   1,089   195  
     Net income (loss) $      35,003  $1,948  $75,085  $(22,078) 
Net income (loss) per share, basic $             0.97  $0.06  $         2.10  $(0.63) 
Net income (loss) per share, diluted $                 0.92  $0.05  $1.99  $(0.63) 
Shares used in computing net income (loss) per share, basic  36,003,931   35,207,276   35,807,264   35,013,072  
Shares used in computing net income (loss) per share, diluted  37,948,049   37,567,176   37,813,107   35,013,072  


Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.